NEUREX
ItalyIt is used as supportive treatment for parkinsonian syndromes.
Frequently asked questions
How should Neurex be taken?
The dose must be determined by a physician. 1-2 ampoules of 500 mg or one ampoule of 1000 mg may be administered via intramuscular or slow intravenous injection (or via infusion pump). In case of intravenous administration, the injection must be very slow.
When should you not use this medicine?
It must not be used in case of hypersensitivity to the active substance or to any of the other components of the medicinal product.
What are the side effects of Neurex?
No side effects related to the drug have been reported at this time.
Are there interactions with other medicines?
The drug can be used together with antihemorrhagics, substances that reduce intracranial pressure, and perfusion fluids. In Parkinson's disease, it acts synergistically with L-dopa, allowing for a reduction in its dosage.
Can it be used during pregnancy or breastfeeding?
The drug is not contraindicated in these cases, but it must be administered only if strictly necessary and under medical supervision.
What should be done in case of intracranial hemorrhage?
In the presence of intracranial hemorrhage, high doses (exceeding 500 mg in a single administration) must not be administered, as they could increase blood flow.
Instructions for use
NEUREX
500 mg/4ml injectable solution 5 vials of 4 ml
1000 mg/4ml injectable solution 3 vials of 4 ml
Citicoline – N06BX06
COMPOSITION
Neurex Neurex
One vial contains “500” “1000”
Sodium citicoline: mg. 522.5 mg. 1045
Equivalent to citicoline mg. 500 mg. 1000
Excipients: Water for injectable preparations.
PHARMACEUTICAL FORM AND CONTENT
Solution for intramuscular or intravenous use.
4 ml vials containing 500 mg or 1000 mg of citicoline.
THERAPEUTIC PHARMACOLOGICAL CATEGORY
N06BX06 – Central nervous system agent.
Marketing Authorization Holder: Euro-Pharma S.r.l. - Via Garzigliana, 8 TORINO
Manufacturer and Final Control:
Pharmaceutical Plant – Special Product’s Line S.p.a. – Via Campobello 15 – Pomezia (Rm)
THERAPEUTIC INDICATIONS
Supportive treatment of parkinsonian syndromes.
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients.
PRECAUTIONS FOR USE
In cases of severe cerebral edema, it is necessary to administer concomitantly drugs that reduce intracerebral pressure, such as mannitol and corticosteroids.
In cases of intracranial hemorrhage, high doses (above 500 mg in a single administration) must not be administered, as they may increase blood flow.
INTERACTIONS
Exhibits synergistic activity with L-dopa (allowing reduction of its dosage) in Parkinson's disease.
May be used concomitantly with antihemorrhagic agents, substances that reduce intracranial pressure, and perfusion fluids.
SPECIAL WARNINGS
The drug is not contraindicated during pregnancy and lactation. However, in such cases it should be administered only when clearly needed and under medical supervision.
Citicoline does not replace all other necessary therapeutic measures for the various pathological conditions for which it is indicated, but acts as an adjunct and integrative therapy.
KEEP OUT OF REACH OF CHILDREN.
DOSAGE, METHOD AND DURATION OF ADMINISTRATION
According to medical prescription: 1–2 vials of 500 mg, or 1 vial of 1000 mg, administered intramuscularly, by slow intravenous injection, or by intravenous infusion. In case of intravenous administration, inject very slowly.
OVERDOSAGE
No adverse effects related to the drug have been reported.
Nevertheless, it is advisable to inform the attending physician.
WHAT TO DO IF YOU FORGET TO TAKE ONE OR MORE DOSES
Resume therapy as prescribed by your physician.
EFFECTS DUE TO TREATMENT INTERRUPTION
None
UNDESIRABLE EFFECTS
No adverse effects related to the drug have been reported.
Following the instructions contained in this leaflet reduces the risk of undesirable effects.
It is important to inform your doctor or pharmacist of any adverse effect occurring, even if not described in this leaflet.
EXPIRY DATE AND STORAGE
Warning: Do not use the medicine after the expiry date stated on the packaging.
The medicine does not require special storage conditions.
REVISION OF THE PACKAGE LEAFLET BY THE MIN/SAL
9 August 2003 (ref. Ministerial Decree Min/Sal No. 269 and G.U. No. 184)
The original data is available in the language of the country of manufacture.
Data source: Italian Medicines Agency (AIFA)
Data last verified: September 21, 2026